Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Ipatasertib plus paclitaxel in the first-line setting does not confer a progression-free survival (PFS) benefit to patients with PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC), according to a study presented at SABCS 2020.

First-line ipatasertib-paclitaxel fails to show PFS benefit in PIK3CA/AKT1/PTEN-altered aTNBC

COVID-19 vs flu: Far more fatal and damaging

While it is tempting to draw lessons from previous influenza pandemic in dealing with the relatively new COVID-19 pandemic, emerging data show just how much deadlier COVID-19 intrinsically is compared with influenza — with higher rates of deaths and complications among hospitalized patients with COVID-19.

COVID-19 vs flu: Far more fatal and damaging

RASP inhibition gets high marks in early trial of dry eye disease

The novel reactive aldehyde species (RASP) inhibitor reproxalap delivers rapid and meaningful control of signs and symptoms of dry eye disease, according to the results of a phase IIb trial.

RASP inhibition gets high marks in early trial of dry eye disease

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients

The addition of obinutuzumab or rituximab to chemotherapy* (O-CT or R-CT, respectively) similarly led to HRQoL** improvements in patients with previously untreated advanced follicular lymphoma (FL), according to the phase III GALLIUM study.

Obinutuzumab, rituximab improve PROs in follicular lymphoma patients

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

The long-acting glucagon-like peptide 1 receptor agonist exenatide once weekly helps improve glycaemic control but does little to modify carotid plaque volume or composition in patients with type 2 diabetes (T2D), according to the results of a trial.

Exenatide once weekly falls short of reducing carotid plaque progression in T2D

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

02 Feb 2021 bởi

The combination of sofosbuvir plus velpatasvir does as well in the real world as in a Japanese phase III trial in hepatitis C virus (HCV) patients with decompensated cirrhosis, although there have been incidences of treatment discontinuation and liver disease-related death, as reported by a team of researchers.

Sofosbuvir–velpatasvir treatment of HCV with decompensated cirrhosis works in real world

Medication persistence shorter in new users of tofacitinib for rheumatoid arthritis

Treatment discontinuation with tofacitinib is common in patients with rheumatoid arthritis (RA) despite its ease of administration, reports a new study.

Medication persistence shorter in new users of tofacitinib for rheumatoid arthritis

Long-term tacrolimus therapy safe, effective in lupus nephritis

02 Feb 2021 bởi

Maintenance treatment with tacrolimus in patients with lupus nephritis (LN) over 5 years is effective and well tolerated in the real-world clinical setting, results of a postmarketing surveillance (PMS) study in Japan have shown.

Long-term tacrolimus therapy safe, effective in lupus nephritis

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer

02 Feb 2021 bởi

In the final analysis of the phase III ClarIDHy trial, ivosidenib was well-tolerated and had a favourable overall survival (OS) benefit despite a high crossover rate from placebo among individuals with previously treated advanced cholangiocarcinoma and an isocitrate dehydrogenase 1 mutation (mIDH1 CCA).

Final ClarIDHy findings boost clinical benefit of ivosidenib for rare aggressive biliary cancer